Member Info for Laura2022

The drug below is the poster Pyc/merck Co presented at AACR April 2023

Pembrolizumab Merk.

Segments Insight:

Drug Class Insights:

Based on drug class the global prostate cancer market is categorized into Hormonal ADT, AR-Directed Therapies, Cytotoxic agents, Bone metastases, therapeutic vaccines, PARP inhibitors, Kinase inhibitors, AND PSMA-targeted radioligands. AR-directed therapies is expected to remain the dominant drug class in 2032, accounting for 58% of the total prostate cancer market ($17.4 billion). The apalutamide and enzalutamide will be the best-selling agents in the overall prostate cancer market by 2029, with sales totaling approximately $14.2 billion across the major markets. The rising uptake of apalutamide and enzalutamide in currently approved settings, in addition to anticipated label expansions in hormone-sensitive settings, will help drive the prostate cancer market.

PARP inhibitors are expected to be the second most lucrative drug class, accounting for 16% of total major-market sales. anticipate significant sales of niraparib in combination with abiraterone in the mHSPC setting by 2029 ($2.6 billion); its sales will reflect its high cost and long duration of treatment, rather than its high uptake. The anticipated approval of kinase inhibitors and PSMA-targeted radioligands should also increase major-market sales in 2029.

Prostrate cancer market forecast growth fromm 12 billion in 2022 to 27.5 billion by 2032.

Regards

From a poster called sadoldgit

Looks like some kind of warrant vehicle?

EUDA Health Holdings Limited Warrant (EUDAW)

Nasdaq Listed

What a brilliant summary and Q and A

I am investing in oncology stocks and I have purchased some Avacta today

I hold 3 oncology focused stocks now and I believe 2024 will be a tipping point given the new FDA guidance on precision dosing,modelling and FDA clearance

Each buy is getting more expensive last few days (including the one for £1700 shown in red yesterday )

Have you got the latest chart please

From mgmt?

Update just arrived

, the services segment is expected to witness a significant CAGR during the forecast period, owing to increase in the number key market players providing biosimulation services and the increased awareness & acceptance of biosimulation tools among the researchers and cost savings by opting for biosimulation services.

On the basis of application, the biosimulation industry is segmented into drug discovery, drug development and otherts. The drug discovery segment dominated the market in 2022, owing to surge in demand for personalized medicine and cost and time efficiency provided by biosimulation software in drug discovery as it allows researchers to virtually test and analyze the effects of different drug candidates on biological systems, reducing the need for costly and time-consuming laboratory experiments.

Biosimulation market size was valued at $2.5 billion in 2022, and is estimated to reach $10.6 billion by 2032, growing at a CAGR of 15.8% from 2023 to 2032. Biosimulation is quantitative drug development that powers decision making. Modeling and simulation are proven effective and efficient alternatives to real-world clinical trials. The result is enabling clients to make better medicines available to patients sooner.

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :

Physiomics Plc, Genedata AG, Simulations Plus, Inc., VeriSIM Life, Schrodinger, Inc., SimBioSys, Cadence Design Systems, Inc., Certara, Inc., Dassault Systemes, INOSIM Software GmbH

No problem LL

Enjoy

Thanks Gr33

I thought my error could have been more politely corrected

Have a lovley Xmas

Let's hope the world is a better place next year than this

In terms of shares it feels like bio techs are back on the agenda after a post covid lull

Apologies

There's usually the AACR in March every year ,try that one ‽

The personalised medicine prostate dosing app I at the bottom of this link

Could AVCT be used ?

https://www.physiomics.co.uk/personalised-cancer-treatment/

Have a lovely Xmas all and hope AVCT continues their excellent work

Don't know if it helps or could be used side by side but PYC have a prostate dosing tool that is currently awaiting regulatory approval but has been used as part of a NHS study which concluded Jan 2023

Do you think AVCT and PYC could work side by side ( or are they 2 different types of tech ?)

Thankyou Ralph

I like the "Many opportunities that lay ahead"

Have a great Christmas Ralph and all

EUDA merger must be close

The RNS and the subsequent Q and A said it was in EVERYONE best interest (EUDA/TRX) for it o happen and they would have had to inform NASDAQ it was not

Happy Xmas all

Let's hope 2024 is better for the world peace than this one

Only 150k available to buy , very low amount

Ianbt

Hope you don't mind me asking but you've been very negative on AVCT ABDX and now APTA

You're right ..

APTA IPO and d last 2yrs but I trust Adam Hargreaves who has excellent pedigree

And I'm invested in APTA at current prices ad slightly higher

Have a great Xmas